University of Padua, Legnaro, Padova, Italy; Department of Veterinary Medical Sciences, Alma Mater Studiorum-University of Bologna, Ozzano dell’Emilia, Bologna, Italy
Auto-generated profile, based on publicly available information
Michele Tumbarello
University of Padua, Legnaro, Padova, Italy; Department of Veterinary Medical Sciences, Alma Mater Studiorum-University of Bologna, Ozzano dell’Emilia, Bologna, Italy
Background: Benefit of adding a second-line immunosuppressive drug to glucocorticoids for the treatment of non-associative immune-mediated hemolytic anemia (naIMHA) in dogs has not been defined prospectively. Hypothesis/Objectives: Evaluate the effectiveness of different immunosuppressive protocols in naIMHA dogs. Animals: Forty-three client-owned dogs. Methods: Open label, randomized, clinical trial. Dogs were treated with methylprednisolone (M-group), methylprednisolone plus cyclosporine (MC-group) or methylprednisolone plus mycophenolate mofetil (MM-group). Dogs were defined as responders by disappearance of signs of immune-mediated destruction and hematocrit stabilization. Frequency of responders was compared between M-group and combined protocols (MC and MM-group evaluated together), and among the 3 different therapeutic groups at 14 (T14), 30 (T30), 60 (T60) days after admission. Frequency of complications, length of hospitalization and relapse were also compared. Death rate was evaluated at discharge, T60 and 365 (T365) days. Results: Proportion of responders was not significantly different between M-group and combined protocols (MC and MM-groups), nor among the 3 therapeutic groups at T14, T30, and T60 (P > .17). Frequency of relapse, complications, and length of hospitalization were not significantly different between M-group and dogs treated with combined protocols, nor among the 3 treatment groups (P > .22). Death was significantly more common only for MM-group compared with MC-group at T60 (+42.8%; 95% CI: 11.5–67.4; P = .009), and at T365 (+50%; 95% CI: 17.5–73.2; P = .003). Conclusions and Clinical Importance: Combined immunosuppressive therapy did not improve hematological response in naIMHA.
4 September 2026 in Journal of Veterinary Diagnostic Investigation
The BC-75R Vet (Mindray Animal Medical) is a multi-species hematology analyzer that uses electrical impedance and SF-Cube technology (combining laser scatter, fluorescence, and 3-dimensional analysis) for CBC and reticulocyte analysis. We evaluated its analytical performance and compared it with the Advia 2120i (Siemens), a widely used analyzer in veterinary clinical pathology. CBCs were performed on EDTA-anticoagulated blood samples from 411 dogs and 225 cats submitted for routine testing. Analytical precision, linearity, carryover, and total observed error (TE obs ) were assessed according to ASVCP guidelines. We used a 2120i as the reference method and manual differential counts for WBC evaluation. RIs were calculated from 131 healthy dogs and 53 cats. The BC-75R Vet fulfilled the ASVCP requirements for repeatability (CVs < 5% for most variables) and linearity ( r > 0.97), with negligible carryover. TE obs values were within ASVCP allowable error limits, except for WBC types in QC material, which remained acceptable for in-clinic use. Agreement with the 2120i was acceptable for most RBC-related variables; however, systematic and proportional errors were found for mean corpuscular hemoglobin concentration (MCHC) in both species, and a systematic error for mean corpuscular volume (MCV) was found in dogs. Agreement for WBC and platelet counts was generally good, although discrepancies were noted for monocyte and mean platelet volume in both species. These differences likely reflect methodologic differences and known challenges in feline hematology. Despite these limitations, the BC-75R Vet met ASVCP standards and appears suitable for routine testing in dogs and cats. Manual smear review remains essential in selected cases.